IP Verse

Method Of Treating Cancer Using Selective Estrogen Receptor Modulators - EP3122426

The patent EP3122426 was granted to Duke University on Jan 18, 2023. The application was originally filed on Mar 28, 2015 under application number EP15769394A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3122426

DUKE UNIVERSITY
Application Number
EP15769394A
Filing Date
Mar 28, 2015
Status
Granted And Under Opposition
Dec 16, 2022
Grant Date
Jan 18, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZOct 18, 2023ELKINGTON AND FIFEADMISSIBLE
TEVA PHARMACEUTICALSOct 4, 2023VON KAUFFMANNADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS5681835
INTERNATIONAL-SEARCH-REPORTUS2006116364
OPPOSITIONUS2006116364
OPPOSITIONWO2008002490
OPPOSITIONWO2009137104
OPPOSITIONWO2015149045
SEARCHWO2009137104

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CHANG et al., Methods Enzymol., (20030000), vol. 364, pages 118 - 42-
DESCRIPTION- CHANG et al., Mol Cell Biol., (19990000), vol. 19, no. 12, pages 8226 - 39-
DESCRIPTION- CONNOR et al., Cancer Res., (20010000), vol. 61, no. 7, pages 2917 - 22-
DESCRIPTION- HUANG et al., Mol Endocrinol., (20020000), vol. 16, no. 8, pages 1778 - 92-
DESCRIPTION- MILLER et al., J Med Chem, (20010000), vol. 44, no. 11, pages 1654 - 1657-
DESCRIPTION- NORRIS et al., Science, (19990000), vol. 285, no. 5428, pages 744 - 6-
DESCRIPTION- WARDELL et al., Biochem Pharmacol, (20010000), vol. 82, no. 2, pages 122 - 130-
DESCRIPTION- WARDELL et al., Clin Cancer Res, (20130000), vol. 19, no. 9, pages 2420 - 2431-
DESCRIPTION- WARDELL et al., Mol Endocrinol, (20120000), vol. 26, no. 7, pages 1235 - 1248-
DESCRIPTION- WITTMANN et al., Cancer Res, (20070000), vol. 67, no. 19, pages 9549 - 9560-
OPPOSITION- Anonymous, "Proposed INN: List 115: International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO DRUG INFORMATION, GENEVA, CH, CH , (20160101), vol. 30, no. 2, ISSN 1010-9609, pages 241 - 357, XP009553774-
OPPOSITION- Defriend David J, Howell Anthony, Nicholson Robert I, Anderson Elizabeth, Dowsett Mitchell, Mansel Robert E, Blamey Roger W, Bundred Nigel J, Robertson John F, Saunders Christobel, Baum Michael, Walton Peter, Sutcliffe Frances, Wakeling Alan E, "Investigation of a New Pure Antiestrogen (ICI 182780) in Women with Primary Breast Cancer", Cancer research, American Association for Cancer Research, San Diego, CA . Philadelphia (PA, San Diego, CA . Philadelphia (PA, (19940115), vol. 54, no. 2, ISSN 0008-5472, pages 408 - 414, XP093191767-
OPPOSITION- J.F. Robertson et al., "Comparison of the short-term biological effects of 7a-[9-(4,4,5,5,5-pentafluoropentylsullfnyl)nonyl]estra-1,3,5,(10)-triene-3,17B-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer", Cancer Res, (2001), vol. 61, XP055552204-
OPPOSITION- Morikawa Aki; Jhaveri Komal; Seidman Andrew D., "Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions", Current Breast Cancer Reports, Springer US, Boston, Boston , (20131004), vol. 5, no. 4, doi:10.1007/s12609-013-0120-1, ISSN 1943-4588, pages 293 - 301, XP035340253
OPPOSITION- B.S. Komm et al., "An overview of current and emerging SERMs", Journal of Steroid Biochemistry and Molecular Biology, (2014), vol. 143, doi:10.1016/j.jsbmb.2014.03.003, XP029016105
OPPOSITION- Wu Ya-Ling, Yang Xiaojing, Ren Zhong, Mcdonnell Donald P., Norris John D., Willson Timothy M., Greene Geoffrey L., "Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism", Molecular Cell, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20050501), vol. 18, no. 4, doi:10.1016/j.molcel.2005.04.014, ISSN 1097-2765, pages 413 - 424, XP093142007
OPPOSITION- Karen J. Kieser, Dong Wook Kim, Kathryn E. Carlson, Benita S. Katzenellenbogen, John A. Katzenellenbogen, "Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)", Journal of Medicinal Chemistry, American Chemical Society, (20100422), vol. 53, no. 8, doi:10.1021/jm100047k, ISSN 00222623, pages 3320 - 3329, XP055111550
OPPOSITION- Di Leo Angelo, Jerusalem Guy, Petruzelka Lubos, Torres Roberto, Bondarenko Igor N., Khasanov Rustem, Verhoeven Didier, Pedrini José L., Smirnova Iya, Lichinitser Mikhail R., Pendergrass Kelly, Garnett Sally, Lindemann Justin P.O., Sapunar Francisco, Martin Miguel, "Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20101020), vol. 28, no. 30, doi:10.1200/JCO.2010.28.8415, ISSN 0732-183X, pages 4594 - 4600, XP093142008
SEARCH- MORIKAWA AKI ET AL, "Clinical Trials for Breast Cancer with Brain Metastases: Challenges and New Directions", CURRENT BREAST CANCER REPORTS, SPRINGER US, BOSTON, vol. 5, no. 4, doi:10.1007/S12609-013-0120-1, ISSN 1943-4588, (20131004), pages 293 - 301, (20131004), XP035340253 [A] 1-7 * the whole document *
SEARCH- KOMM BARRY S ET AL, "An overview of current and emerging SERMs", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, (20140322), vol. 143, doi:10.1016/J.JSBMB.2014.03.003, ISSN 0960-0760, pages 207 - 222, XP029016105 [Y] 1-7 * page 208 * * page 217, column l *
SEARCH- KAREN J. KIESER ET AL, "Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)", JOURNAL OF MEDICINAL CHEMISTRY, (20100422), vol. 53, no. 8, doi:10.1021/jm100047k, ISSN 0022-2623, pages 3320 - 3329, XP055111550 [Y] 1-7 * abstract * * page 3320, column l *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents